Table 2 Parameter estimates describing lumefantrine population pharmacokinetics for HIV-malaria co-infected patients treated with artemether-lumefantrine
Parameters | Description | Estimates (95% CI) | BSV (RSE %) (Shrinkage %) | BOV (RSE %) (Shrinkage %) |
|---|---|---|---|---|
Ka (hr-1) | Absorption rate constant | 0.032 (0.029-0.034) | 29% (18) (30) | Â |
Vc/F (liters) | Central volume | 25.6 (16.21-34.99) | 82% (24) (51) | Â |
CL/F (liters/hr) | Clearance | 4.54 (3.913-5.167) | 0* | 19% (22) (44) |
Q/F (liters/hr) | Inter-compartmental exchange Clearance | 1.23 (0.99-1.47) | 27% (24) (23) | Â |
Vp/F (liters) | Peripheral Volume | 203 (167.13-238.87) | 39% (22) (37) | Â |
t lag (hr) | Absorption lag time | 1.45 (1.25-1.65 ) | 0* | Â |
F1 | Bioavailability (population typical value) | 1* | 47% (11) (5) | Â |
F1 EFV | Relative bioavailability for patients on Efavirenz | 0.42 (0.34-0.5) | Â | Â |
F1 NEV | Relative bioavailability for patients on Nevirapine | 1.32 (1.08-1.52) | Â | Â |
ADD | Additive residual error | 26.30 (4.15-48.44) | Â | Â |
PROP | Proportion residual error | 0.083 (0.06-0.10) | Â | Â |